Developing drugs that target a major unmet need in cancer.

A Powerful ApproachShare

Threshold is a biotechnology company focused on the discovery and development of therapeutics that selectively target Tumor Hypoxia, a property of solid tumors and some hematologic cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Our lead compound TH-302 has been tested in more than 330 patients and has demonstrated positive responses in a broad variety of tumors.